Thiru M Annaswamy1,2, Kanchan Bahirat3, Gargi Raval4, Yu Yen Chung5, Tri Pham6, Balakrishnan Prabhakaran5. 1. Department of Physical Medicine & Rehabilitation, Penn State Health Milton S. Hershey Medical Center, Hershey, PA, USA. tannaswamy@pennstatehealth.psu.edu. 2. Penn State Health Rehabilitation Hospital, Hummelstown, PA, USA. tannaswamy@pennstatehealth.psu.edu. 3. Simbe Robotics, South San Francisco, CA, USA. 4. Physical Medicine & Rehabilitation Service, VA North Texas Health Care System, Dallas, USA. 5. Department of Computer Science, UT Dallas, Dallas, TX, USA. 6. UT Southwestern Medical School, Dallas, TX, USA.
Abstract
BACKGROUND: To assess the clinical feasibility of a virtual mirror therapy system in a pilot sample of patients with phantom pain. METHODS: Our Mixed reality system for Managing Phantom Pain (Mr. MAPP) mirrors the preserved limb to visualize the amputated limb virtually and perform exercises. Seven patients with limb loss and phantom pain agreed to participate and received the system for 1-month home use. Outcome measures were collected at baseline and 1 month. RESULTS: Four (of seven recruited) participants completed the study, which was temporarily suspended due to COVID-19 restrictions. At 1 month, in-game data showed a positive trend, but pain scores showed no clear trends. Functioning scores improved for 1 participant. CONCLUSIONS: Mr. MAPP is feasible and has the potential to improve pain and function in patients with phantom pain. TRIAL REGISTRATION: Clinical Trials Registration, NCT04529083.
BACKGROUND: To assess the clinical feasibility of a virtual mirror therapy system in a pilot sample of patients with phantom pain. METHODS: Our Mixed reality system for Managing Phantom Pain (Mr. MAPP) mirrors the preserved limb to visualize the amputated limb virtually and perform exercises. Seven patients with limb loss and phantom pain agreed to participate and received the system for 1-month home use. Outcome measures were collected at baseline and 1 month. RESULTS: Four (of seven recruited) participants completed the study, which was temporarily suspended due to COVID-19 restrictions. At 1 month, in-game data showed a positive trend, but pain scores showed no clear trends. Functioning scores improved for 1 participant. CONCLUSIONS: Mr. MAPP is feasible and has the potential to improve pain and function in patients with phantom pain. TRIAL REGISTRATION: Clinical Trials Registration, NCT04529083.
Authors: Patti L Ephraim; Stephen T Wegener; Ellen J MacKenzie; Timothy R Dillingham; Liliana E Pezzin Journal: Arch Phys Med Rehabil Date: 2005-10 Impact factor: 3.966